|
1）Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin. Proc. 2006; 81: 159-66
|
|
|
|
|
2）Najean Y, Rain JD. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol. 1997; 34: 6-16
|
|
|
|
|
3）Mesa RA, Li C-Y, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005; 105: 973-7
|
|
|
|
|
|
4）James C, Ugo V, Le Couédic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434: 1144-8
|
|
|
|
|
5）Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365: 1054-61
|
|
|
|
|
|
6）Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369: 2379-90
|
|
|
|
|
|
7）Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3: e270
|
|
|
|
|
|
8）Mullally A, Lane SW, Ball B, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010; 17: 584-96
|
|
|
|
|
|
9）Shide K, Shimoda HK, Kumano T, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia. 2008; 22: 87-95
|
|
|
|
|
|
10）Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006; 107: 4274-81
|
|
|
|
|
|
11）DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7: 11-20
|
|
|
|
|
|
12）James C, Mazurier F, Dupont S, et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood. 2008; 112: 2429-38
|
|
|
|
|
|
13）Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol. 2011; 29: 1356-63
|
|
|
|
|
|
14）Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363: 1117-27
|
|
|
|
|
|
15）Kleppe M, Kwak M, Koppikar P, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015; 5: 316-31
|
|
|
|
|
|
16）Fleischman AG, Aichberger KJ, Luty SB, et al. TNF-α facilitates clonal expansion of JAK2 V617F positive cells in myeloproliferative neoplasms. Blood. 2011; 118: 6392-8
|
|
|
|
|
|
17）Reynaud D, Pietras E, Barry-Holson K, et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell. 2011; 20: 661-73
|
|
|
|
|
|
18）Devireddy LR, Teodoro JG, Richard FA, et al. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science. 2001; 293: 829-34
|
|
|
|
|
|
19）Goetz DH, Holmes MA, Borregaard N, et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell. 2002; 10: 1033-43
|
|
|
|
|
|
20）Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004; 432: 917-21
|
|
|
|
|
|
21）Yang J, Bielenberg DR, Rodig SJ, et al. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A. 2009; 106: 3913-8
|
|
|
|
|
|
22）Yan Q-W, Yang Q, Mody N, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes. 2007; 56: 2533-40
|
|
|
|
|
|
23）Viau A, El Karoui K, Laouari D, et al. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest. 2010; 120: 4065-76
|
|
|
|
|
|
24）Lin H, Monaco G, Sun T, et al. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Oncogene. 2005; 24: 3246-256
|
|
|
|
|
|
25）Leng X, Lin H, Ding T, et al. Lipocalin 2 is required for BCR-ABL-induced tumorigenesis. Oncogene. 2008; 27: 6110-9
|
|
|
|
|
|
26）Sheng Z, Wang S-Z, Green MR. Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R. EMBO J. 2009; 28: 866-76
|
|
|
|
|
|
27）Kagoya Y, Yoshimi A, Tsuruta-Kishino T, et al. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. Blood. 2014; 124: 2996-3006
|
|
|
|
|
|
28）Rampal R, Mascarenhas J. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm. Curr Opin Hematol. 2014; 21: 65-71
|
|
|
|
|
|
29）Beer PA, Delhommeau F, LeCouédic J-P, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010; 115: 2891-900
|
|
|
|
|
|
30）Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood. 2006; 108: 3548-55
|
|
|
|
|
|
31）Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007; 110: 375-9
|
|
|
|
|
|
32）Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008; 118: 560-70
|
|
|
|
|
|
33）Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med. 1999; 5: 828-31
|
|
|
|
|
|
34）Li J, Sejas DP, Zhang X, et al. TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J Clin Invest. 2007; 117: 3283-95
|
|
|
|
|
|
35）Lu M, Xia L, Liu Y-C, et al. Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. Blood. 2015; 126: 972-82
|
|
|
|
|
|
36）Rodvold JJ, Mahadevan NR, Zanetti M. Lipocalin 2 in cancer: When good immunity goes bad. Cancer Lett. 2012; 316: 132-8
|
|
|
|
|
|
37）Leng X, Ding T, Lin H, et al. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 2009; 69: 8579-84
|
|
|
|
|
|
38）Hu L, Hittelman W, Lu T, et al. NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest. 2009; 89: 531-48
|
|
|
|
|